These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 29402439)
1. Drug development and clinical trial design in pancreatico-biliary malignancies. Harrington J; Carter L; Basu B; Cook N Curr Probl Cancer; 2018; 42(1):73-94. PubMed ID: 29402439 [TBL] [Abstract][Full Text] [Related]
2. Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors. Yoo C; Lamarca A; Choi HJ; Vogel A; Pishvaian MJ; Goyal L; Ueno M; Märten A; Teufel M; Geng L; Morizane C Future Oncol; 2024; 20(16):1069-1077. PubMed ID: 38214149 [TBL] [Abstract][Full Text] [Related]
3. Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers. Kim EJ; Semrad TJ; Bold RJ Expert Opin Investig Drugs; 2015 Jun; 24(6):781-94. PubMed ID: 25809274 [TBL] [Abstract][Full Text] [Related]
4. Emerging molecular target antagonists for the treatment of biliary tract cancer. Lombardi P; Marino D; Fenocchio E; Chilà G; Aglietta M; Leone F Expert Opin Emerg Drugs; 2018 Mar; 23(1):63-75. PubMed ID: 29468924 [TBL] [Abstract][Full Text] [Related]
6. Nivolumab: an investigational agent for the treatment of biliary tract cancer. Di Federico A; Rizzo A; Ricci AD; Frega G; Palloni A; Tavolari S; Brandi G Expert Opin Investig Drugs; 2021 Apr; 30(4):325-332. PubMed ID: 33307866 [No Abstract] [Full Text] [Related]
7. [Current aspects of chemotherapy of metastatic pancreatic and biliary tract carcinomas]. Bokemeyer C; Kollmannsberger C; Oettle H; Kanz L Praxis (Bern 1994); 2000 Sep; 89(39):1545-52. PubMed ID: 11068508 [TBL] [Abstract][Full Text] [Related]
8. Expression of the caudal-type homeodomain transcription factors CDX 1/2 and outcome in carcinomas of the ampulla of Vater. Hansel DE; Maitra A; Lin JW; Goggins M; Argani P; Yeo CJ; Piantadosi S; Leach SD; Biankin AV J Clin Oncol; 2005 Mar; 23(9):1811-8. PubMed ID: 15774774 [TBL] [Abstract][Full Text] [Related]
9. Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trial. Limani P; Linecker M; Kron P; Samaras P; Pestalozzi B; Stupp R; Jetter A; Dutkowski P; Müllhaupt B; Schlegel A; Nicolau C; Lehn JM; Petrowsky H; Humar B; Graf R; Clavien PA BMC Cancer; 2016 Oct; 16(1):812. PubMed ID: 27756258 [TBL] [Abstract][Full Text] [Related]
10. Emerging treatment with systemic chemotherapy and targeted agents for biliary cancers. Boku N Curr Opin Investig Drugs; 2010 Jun; 11(6):653-60. PubMed ID: 20496260 [TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Mulder K; Koski S; Scarfe A; Chu Q; King K; Spratlin J Oncotarget; 2010 Nov; 1(7):515-529. PubMed ID: 21317448 [TBL] [Abstract][Full Text] [Related]
12. Systemic therapy for biliary cancers. Jordan E; Abou-Alfa GK; Lowery MA Chin Clin Oncol; 2016 Oct; 5(5):65. PubMed ID: 27829278 [TBL] [Abstract][Full Text] [Related]
13. The challenge of treating older patients with pancreaticobiliary malignancies. Corrigan LR; Bracken-Clarke DM; Horgan AM Curr Probl Cancer; 2018; 42(1):59-72. PubMed ID: 29459178 [TBL] [Abstract][Full Text] [Related]
14. Pathologic staging of pancreatic, ampullary, biliary, and gallbladder cancers: pitfalls and practical limitations of the current AJCC/UICC TNM staging system and opportunities for improvement. Adsay NV; Bagci P; Tajiri T; Oliva I; Ohike N; Balci S; Gonzalez RS; Basturk O; Jang KT; Roa JC Semin Diagn Pathol; 2012 Aug; 29(3):127-41. PubMed ID: 23062420 [TBL] [Abstract][Full Text] [Related]
16. New developments in systemic therapy for advanced biliary tract cancer. Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894 [TBL] [Abstract][Full Text] [Related]
17. Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure. Onesti CE; Romiti A; Roberto M; Falcone R; Marchetti P Expert Rev Anticancer Ther; 2015; 15(10):1183-98. PubMed ID: 26325474 [TBL] [Abstract][Full Text] [Related]
18. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials. Mosquera C; Maglic D; Zervos EE Cancer Genet; 2016 Dec; 209(12):567-581. PubMed ID: 27613577 [TBL] [Abstract][Full Text] [Related]
19. Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials. Kaur J; Singh P; Enzler T; Sahai V Expert Opin Emerg Drugs; 2021 Jun; 26(2):103-129. PubMed ID: 33734833 [No Abstract] [Full Text] [Related]
20. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415. Adis International Ltd Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]